Regulatory flexibility can make continuous improvement possible.
Samantha Sheridan
Advertisement
Samantha Sheridan is the director of regulatory affairs at Shire Pharmaceuticals
Articles by Samantha Sheridan
Second in a three-part series that discusses the complexities of QbD implementation in biotech development.
First in a three-part series that discusses the complexities of QbD implementation in biotech product development.
Advertisement
Latest Updated Articles
Quality by Design for Biotechnology Products—Part 3Published: January 1st 2010 | Updated:
Quality by Design for Biotechnology Products—Part 2Published: December 1st 2009 | Updated:
Quality by Design for Biotechnology Products—Part 1Published: November 1st 2009 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Ask the Expert: Commenting on Draft Regulations
2
A-TEEM: A Novel, Powerful Tool for Evaluating and Monitoring Cell Culture Media
3
Behind the Headlines Episode 27: Unpacking Mega Deals and R&D Directions
4
Global Study Confirms Survival Advantage of Mogamulizumab in Advanced Mycosis Fungoides and Sézary Syndrome
5
